Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Eagle Pharmaceuticals (NQ: EGRX )

2.140 UNCHANGED
Last Price Updated: 4:00 PM EDT, Oct 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eagle Pharmaceuticals

< Previous 1 2 3 4 5 6 Next >
Eagle Pharmaceuticals to Present at Piper Sandler 33rd Annual Healthcare Conference 2021
From Eagle Pharmaceuticals, Inc.
Via Business Wire
Eagle Pharmaceuticals, inc (EGRX) Q3 2021 Earnings Call Transcript
EGRX earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces... 
Via Benzinga
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... 
Via Benzinga
Exposures Product Safety
Eagle Pharmaceuticals Reports Third Quarter 2021 Results
From Eagle Pharmaceuticals, Inc.
Via Business Wire
Eagle Pharmaceuticals to Host Third Quarter 2021 Financial Results on November 9, 2021
From Eagle Pharmaceuticals, Inc.
Via Business Wire
Reminder: Eagle Pharmaceuticals to Host CAL02 Investor Event on September 9, 2021
From Eagle Pharmaceuticals, Inc.
Via Business Wire
Eagle Pharmaceuticals to Present at September Healthcare Conferences
From Eagle Pharmaceuticals, Inc.
Via Business Wire
The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 4) Avadel Pharmaceuticals plc (... 
Via Benzinga
The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks... 
Via Benzinga
Exposures Product Safety
33 Stocks Moving In Tuesday's Mid-Day Session
Gainers AC Immune SA (NASDAQ: ACIU) shares jumped 68.4% to $11.77. AC Immune and its collaborating partner Genentech, part of Roche Holdings, announced topline data from Phase 2... 
Via Benzinga
The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29) Acceleron Pharma Inc. (... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 27) Acceleron Pharma Inc. (... 
Via Benzinga
Eagle Pharmaceuticals Wins Vasopressin Patent Trial
From Eagle Pharmaceuticals, Inc.
Via Business Wire
The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 31) AC Immune SA (NASDAQ: ACIU... 
Via Benzinga
Eagle Pharmaceuticals Granted Additional Patent for Bendamustine Franchise
From Eagle Pharmaceuticals, Inc.
Via Business Wire
The Daily Biotech Pulse: Lilly Strikes $1.6B R&D Collaboration, FSD Pulls Plug On COVID-19 Program, Cassava Sinks On Questions About Alzheimer's Drug
ere's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 24) Agenus Inc. (NASDAQ: AGEN)... 
Via Benzinga
Exposures COVID-19
55 Biggest Movers From Yesterday
Gainers Unico American Corporation (NASDAQ: UNAM) shares gained 59% to close at $4.15 on Tuesday. Elys Game Technology, Corp. (NASDAQ: ELYS) rose 43% to close at $6.62 after it... 
Via Benzinga
Eagle Pharmaceuticals Announces Worldwide Licensing Agreement with Combioxin SA for Phase 2b/3, Novel First-in-Class Antitoxin Agent CAL02 in Development for Combination Use with Antibiotics for the Treatment of Severe Pneumonia
From Eagle Pharmaceuticals, Inc.
Via Business Wire
Eagle Pharmaceuticals, inc (EGRX) Q2 2021 Earnings Call Transcript
EGRX earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Eagle Pharmaceuticals In-Licenses US Rights For Emergency Hospital Product, Q2 Earnings Beat Consensus
Eagle Pharmaceuticals Inc (NASDAQ: EGRX) has entered into a licensing agreement with AOP Orphan Pharmaceuticals GmbH for the commercial rights to its product,... 
Via Benzinga
Topics Earnings
Exposures Financial
Recap: Eagle Pharmaceuticals Q2 Earnings
Shares of Eagle Pharmaceuticals (NASDAQ:EGRX) were unchanged after the company reported Q2 results. Quarterly Results Earnings per share were up 63.16% year over year to $0... 
Via Benzinga
Eagle Pharmaceuticals Reports Second Quarter 2021 Results
From Eagle Pharmaceuticals, Inc.
Via Business Wire
Eagle Pharmaceuticals Announces Licensing Agreement with AOP Orphan for U.S. Commercial Rights to Landiolol, a Beta-1 Adrenergic Blocker
From Eagle Pharmaceuticals, Inc.
Via Business Wire
Eagle Pharmaceuticals to Host Second Quarter 2021 Financial Results on August 9, 2021
From Eagle Pharmaceuticals, Inc.
Via Business Wire
Eagle Pharmaceuticals Announces FDA Maintains Prioritization of ANDA for Vasopressin
From Eagle Pharmaceuticals, Inc.
Via Business Wire
Eagle Pharmaceuticals: Return On Capital Employed Insights
During Q1, Eagle Pharmaceuticals (NASDAQ:EGRX) brought in sales totaling $41.25 million. However, earnings decreased 138.53%, resulting in a loss of $3.77 million. In Q4, Eagle... 
Via Benzinga
Eagle Pharmaceuticals Submits Response to Complete Response Letter from FDA for Vasopressin
From Eagle Pharmaceuticals, Inc.
Via Business Wire
Return On Capital Employed Overview: Eagle Pharmaceuticals
During Q1, Eagle Pharmaceuticals (NASDAQ:EGRX) brought in sales totaling $41.25 million. However, earnings decreased 138.53%, resulting in a loss of $3.77 million. Eagle... 
Via Benzinga
Eagle Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference 2021
From Eagle Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.